Ryan Cross

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes will help solve some of the biggest and most competitive challenges in the cell and gene therapy field.

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher and CHOP to develop custom therapies for HLH and metabolic disorders.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein nanoparticles. CEO Akin Akinc leads development for autoimmune diseases.

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology. Despite raising $115M, the company struggled with targeting and delivery issues.

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication syndrome, showing improved motor skills after 12 weeks.

Alzheon's valiltramiprosate (ALZ-801) fails Phase 3 trial in Alzheimer's patients with APOE4 gene copies, showing no significant cognitive decline slowdown despite safer profile than competitors.

Gene editing pioneer David Liu was awarded one of three Breakthrough Prizes in Life Sciences for his invention of base and prime editing. The two CRISPR technologies, first published in ...

Shanghai's RiboX Therapeutics begins first-ever circular RNA clinical trial, targeting dry mouth in cancer patients. Company has raised $110M from investors including Boehringer Ingelheim.

Alpha Lee announced a Zika virus-fighting molecule at a chemistry meeting, but later learned his $67M federal funding was cut due to pandemic's end, affecting multiple antiviral research programs.

Turn Biotechnologies acquires drug delivery tech from Harvard & Vesigen Therapeutics to expand mRNA aging therapies; CEO Anja Krammer aims for 2026 clinical trials